Muscle-Specific DNM2 Overexpression Improves Charcot–Marie–Tooth Disease In Vivo and Reveals a Narrow Therapeutic Window in Skeletal Muscle
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27031471 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Marie Goret und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Genetics and Molecular and Cellular Biology (IGBMC), INSERM U1258, CNRS UMR7104, University of Strasbourg, 67404 Illkirch, France. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Muscle, Skeletal, Dynamin II. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IdEx Unistra, SFRI- STRAT'US project, EUR IMCBio.
Abstract (Originalsprache)
Charcot–Marie–Tooth disease (CMT), caused by dominant loss-of-function mutations in DNM2, encoding the GTPase dynamin-2, impairs motor and sensory function. However, the respective contributions of muscle and nerve pathology, and the therapeutic potential of increasing DNM2 expression, remain unresolved. We evaluated tissue-targeted and systemic approaches to increase DNM2 in a mouse model carrying the common K562E-CMT mutation. Muscle-specific DNM2 overexpression from embryogenesis in Dnm2K562E/+ mice ameliorated desmin and integrin mislocalization, membrane trafficking defects, mitochondrial abnormalities, and fibrosis in skeletal muscle, resulting in improved locomotor coordination despite persistent muscle atrophy. Conversely, systemic postnatal AAV delivery of human DNM2 increased DNM2 in muscle but failed to transduce nerves and paradoxically worsened the muscle pathology, producing centronuclear myopathy-like features. These findings reveal a primary pathogenic impact of DNM2-CMT mutation within skeletal muscle, independent of nerve involvement. Collectively, they underscore that precise DNM2 dosage is critical for neuromuscular homeostasis and reveal a narrow therapeutic window for safe and effective therapeutic intervention. This paradox, in which efforts to compensate for a loss-of-function neuropathy risk inducing a gain-of-function myopathy, highlights the need for tightly controlled modulation of DNM2 activity in future therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Genetics and Molecular and Cellular Biology (IGBMC), INSERM U1258, CNRS UMR7104, University of Strasbourg, 67404 Illkirch, France.
ORCID-Profile: Marie Goret, Jocelyn Laporte
Förderung
- IdEx Unistra
- SFRI- STRAT'US project
- EUR IMCBio
- CMT-GM
- SFRI-STRAT’US project
- ANR CMT-GM
- French National Research Agency
Zitieren
APA
Goret, M., Piccolo, G., & Laporte, J. (2026). Muscle-Specific DNM2 Overexpression Improves Charcot–Marie–Tooth Disease In Vivo and Reveals a Narrow Therapeutic Window in Skeletal Muscle. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031471
Vancouver
Goret M, Piccolo G, Laporte J. Muscle-Specific DNM2 Overexpression Improves Charcot–Marie–Tooth Disease In Vivo and Reveals a Narrow Therapeutic Window in Skeletal Muscle. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031471
BibTeX
@article{Goret2026,
author = {Goret, Marie and Piccolo, Gwenaelle and Laporte, Jocelyn},
title = {Muscle-Specific DNM2 Overexpression Improves Charcot–Marie–Tooth Disease In Vivo and Reveals a Narrow Therapeutic Window in Skeletal Muscle},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27031471}
}
EUVIMED